Offer - Urjas Oil for just ₹ 1
Bortrac 3.5 Mg Injection, a prescription drug, is manufactured in various forms such as Injection. It is typically used for the treatment of Multiple Myeloma. Bortrac 3.5 Mg Injection also has some secondary and off-label uses. These are listed below.
The correct dosage of Bortrac 3.5 Mg Injection depends on the patient's age, gender, and medical history. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. Refer to the dosage section for a detailed discussion.
Besides the aforementioned side effects, there are other adverse effects of Bortrac 3.5 Mg Injection as well, which are listed below. These side effects of Bortrac 3.5 Mg Injection are usually temporary and subside with the completion of treatment. However, if these continue for a longer time, consult your doctor right away.
Bortrac 3.5 Mg Injection's effect during pregnancy is Severe and Severe while nursing. In addition, Bortrac 3.5 Mg Injection's effects on the liver, heart and kidney are discussed below in the Bortrac 3.5 Mg Injection related warnings section.
Individuals suffering from medical conditions like Gastrointestinal Bleeding must refrain from the use of Bortrac 3.5 Mg Injection since this can cause severe adverse effects. Other conditions have been mentioned below in the Bortrac 3.5 Mg Injection contraindications section.
Additionally, Bortrac 3.5 Mg Injection may also adversely react with other medicines. See below for a complete list.
In addition to the above precautions for Bortrac 3.5 Mg Injection, it is important to know that it is not safe while driving, and is not habit-forming.
Bortrac 3.5 Mg Injection is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
Is the use of Bortrac 3.5 Mg Injection safe for pregnant women?
Bortrac should not be taken during pregnancy, or should only be taken on the advice of a doctor as it may have severe side effects.
Is the use of Bortrac 3.5 Mg Injection safe during breastfeeding?
Taking Bortrac may lead to serious side effects if you are breastfeeding. Bortrac should not be taken by breastfeeding women unless prescribed by the doctor.
What is the effect of Bortrac 3.5 Mg Injection on the Kidneys?
Bortrac does not damage the kidneys.
What is the effect of Bortrac 3.5 Mg Injection on the Liver?
You may experience side effects on your liver after taking Bortrac. If this happens, then discontinue its use. Consult your medical practitioner, do as he/she suggests.
What is the effect of Bortrac 3.5 Mg Injection on the Heart?
Bortrac may cause harmful effects on the heart. if you feel it's having any such effect, then stop taking this drug, and restart only on your doctor's advice.
If you are suffering from any of the following diseases, you should not take Bortrac 3.5 Mg Injection unless your doctor advises you to do so -
Is this Bortrac 3.5 Mg Injection habit forming or addictive?
No, there is no any evidence that Bortrac 3.5 Mg Injection is addictive.
Is it safe to drive or operate heavy machinery when consuming?
You may feel sleepy or tired after taking Bortrac 3.5 Mg Injection. So it is best to avoid driving.
Is it safe?
Yes, but consume Bortrac 3.5 Mg Injection only on doctor's advice.
Is it able to treat mental disorders?
No, Bortrac 3.5 Mg Injection is not used to treat mental disorders.
Interaction between Food and Bortrac 3.5 Mg Injection
Taking Bortrac 3.5 Mg Injection with some specific foods may delay its effect. Talk to your doctor about this.
Interaction between Alcohol and Bortrac 3.5 Mg Injection
It is difficult to say anything about the effect of Bortrac 3.5 Mg Injection and alcohol. No research has been done on this yet.
This medicine data has been created by -
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 234-235
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 871
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Velcade® (bortezomib)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Bortezomib Aft (Bortezomib)
